Literature DB >> 26641139

Factors associated with antiretroviral treatment uptake and adherence: a review. Perspectives from Australia, Canada, and the United Kingdom.

K Bolsewicz1, J Debattista2, A Vallely3,4, A Whittaker5, L Fitzgerald1.   

Abstract

International focus on reducing onward HIV transmission emphasizes the need for routine HIV testing and early uptake of antiretroviral treatment (ART). Strategic targets have been set for 2020 to achieve the goal of 90% of people infected with HIV diagnosed, 90% of identified cases on treatment, and 90% of persons on treatment virally suppressed (90-90-90). It is vital to understand the complexity of factors influencing a person's treatment decisions over time and the context which may enable better adherence. In this paper we present findings from the review of published and gray literature (2003-2013) on the documented factors associated with treatment initiation and adherence in the general adult population of Australia, Canada, and the UK. A framework developed by Begley, McLaws, Ross, and Gold [2008. Cognitive and behavioural correlates of non-adherence to HIV anti-retroviral therapy: Theoretical and practical insight for clinical psychology and health psychology. Clinical Psychologist, 12(1), 9-17] in Australia was adapted to summarize the findings. A systematic database search using keywords and a set of inclusion criteria yielded 17 studies (Australia = 6; Canada = 8; UK = 3). In addition 11 reports were included in the review. We found that a person's abilities and motivations (intrapersonal factors, reported in 7 studies) to start and continue ART are influenced by a host of interconnected factors spanning relationship (interpersonal, 3 studies) and broader structural (extrapersonal, 15 studies) factors that are situated within social determinants of health. People therefore evaluate various costs and benefits of starting and staying on treatment, in which biomedical concerns play an important yet often subsidiary role. In this review the economic barriers to care were found to be significant and under-reported, highlighting the persistent health inequities in terms of access to services. Our understanding of the context around people's use of ART remains poor. Qualitative social research within HIV-positive communities is urgently needed to capture people's lived experiences and may address some of this deficit in understanding.

Entities:  

Keywords:  ART; ART: antiretroviral treatment; the UK: United Kingdom; HIV: human immunodeficiency virus; AIDS: acquired immunodeficiency syndrome; PLHIV: people living with HIV; the USA: United States of America; IDU: injecting drug user; PBS: Pharmaceutical Benefits Sc; Australia; Canada; UK; factors; review

Mesh:

Substances:

Year:  2015        PMID: 26641139     DOI: 10.1080/09540121.2015.1114992

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  19 in total

1.  Abstracts of the HIV & Hepatitis in the Americas 2017 - Congress.

Authors: 
Journal:  J Int AIDS Soc       Date:  2017-04-06       Impact factor: 5.396

2.  Examining engagement in care of women living with HIV in South India.

Authors:  Sara Chandy; Elsa Heylen; B N Ravikumar; Maria L Ekstrand
Journal:  Health Care Women Int       Date:  2019-06-26

3.  Adherence to Antiretroviral Therapy and Its Predictive Factors Among People Living with HIV in China: A Behavioral Theory-Based Prospective Cohort Study.

Authors:  Qiangsheng He; Chun Hao; Deng Pan; Cong Liu; Kai Zhou; Jinghua Li; Haidan Zhong; Peishan Du; Quanmin Li; Joseph T F Lau; Yuantao Hao; Linghua Li; Jing Gu; Weiping Cai
Journal:  Int J Behav Med       Date:  2022-09-14

4.  Developing a patient-reported outcome measure for HIV care on perceived barriers to antiretroviral adherence: assessing the needs of HIV clinicians through qualitative analysis.

Authors:  Isabelle Toupin; Kim Engler; David Lessard; Leo Wong; Andràs Lènàrt; Bruno Spire; François Raffi; Bertrand Lebouché
Journal:  Qual Life Res       Date:  2017-10-13       Impact factor: 4.147

5.  Dose-related and contextual aspects of suboptimal adherence to antiretroviral therapy among persons living with HIV in Western Europe.

Authors:  Babatunde Akinwunmi; Daniel Buchenberger; Jenny Scherzer; Martina Bode; Paolo Rizzini; Fabio Vecchio; Laetitia Roustand; Gaelle Nachbaur; Laurent Finkielsztejn; Vasiliki Chounta; Nicolas Van de Velde
Journal:  Eur J Public Health       Date:  2021-07-13       Impact factor: 3.367

6.  Decreased Time From Human Immunodeficiency Virus Diagnosis to Care, Antiretroviral Therapy Initiation, and Virologic Suppression during the Citywide RAPID Initiative in San Francisco.

Authors:  Oliver Bacon; Jennie Chin; Stephanie E Cohen; Nancy A Hessol; Darpun Sachdev; Susa Coffey; Susan Scheer; Susan Buchbinder; Diane V Havlir; Ling Hsu
Journal:  Clin Infect Dis       Date:  2021-07-01       Impact factor: 20.999

Review 7.  Microbiota and Probiotics in Health and HIV Infection.

Authors:  Chiara D'Angelo; Marcella Reale; Erica Costantini
Journal:  Nutrients       Date:  2017-06-16       Impact factor: 5.717

8.  An Efficient Microarray-Based Genotyping Platform for the Identification of Drug-Resistance Mutations in Majority and Minority Subpopulations of HIV-1 Quasispecies.

Authors:  Verónica Martín; Celia Perales; María Fernández-Algar; Helena G Dos Santos; Patricia Garrido; María Pernas; Víctor Parro; Miguel Moreno; Javier García-Pérez; José Alcamí; José Luis Torán; David Abia; Esteban Domingo; Carlos Briones
Journal:  PLoS One       Date:  2016-12-13       Impact factor: 3.240

Review 9.  Barriers to treatment: describing them from a different perspective.

Authors:  Francesca Devine; Taylor Edwards; Steven R Feldman
Journal:  Patient Prefer Adherence       Date:  2018-01-17       Impact factor: 2.711

10.  HIV pharmaceutical care in primary healthcare: Improvement in CD4 count and reduction in drug-related problems.

Authors:  C G R C Molino; Renata Cavalcanti Carnevale; Aline Teotonio Rodrigues; Patricia Moriel; Priscila Gava Mazzola
Journal:  Saudi Pharm J       Date:  2016-11-15       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.